Citations

Clear

3030 citation(s) found for "Susan, M".

ACE2 deficiency protects against heme protein-induced acute kidney injury
Croatt, Anthony J., Singh, Raman Deep , Grande, Joseph P. , Ackerman, Allan W., Gurley, Susan B. , Juncos, Luis A. , Nath, Karl A. , Juncos, Luis A , Nath, Karl A , Barry, Michael A.

Mayo Clinic

American Journal of Physiology-Renal Physiology | March 25, 2025 | Volume: 328 | Issue: 5 | Pages: F676-F683

10.1152/ajprenal.00061.2025 | PMID 40131861 Get It

ACE2 protein binds heme, which we reasoned would promote heme entry into the kidney and, accordingly, heme protein-mediated acute kidney injury. Our findings support this hypothesis. This study is the first to demonstrate the biological relevance of ACE2-heme binding, uncover a new pathway of heme-dependent kidney injury, and identify myoglobin and heme as novel determinants of ACE2 expression. Our study explains why plasma levels of myoglobin and heme predict poor outcomes in patients with COVID-19.
Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI
Lagarde, Julien , Blazhenets, Ganna , Zhang, J. , Eloyan, Ani , Thangarajah, Maryanne, Taurone, Alexander, Allen, Isabel Elaine , Soleimani‐Meigooni, David N. , Zeltzer, Ehud , Windon, Charles , Raya, Maison Abu , Smith, Karen, Shankar, Ranjani , Amuiri, Alinda, Rocha, Salma, Hammers, Dustin B. , Dage, Jeffrey L. , Kirby, Kala, Aisen, Paul, Koeppe, Robert, Landau, Susan, Carrillo, María C. , Touroutoglou, Alexandra , Brickhouse, Michael , Raman, Rema , Day, Gregory S. , Duara, Ranjan, Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Grant, Ian , Rogalskı, Emily , Johnson, Erik C. B. , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Apostolova, Liana G. , Joie, Renaud La , Rabinovici, Gil D. , Blazhenets, Ganna , Soleimani-Meigooni, David , Zeltzer, Ehud , Windon, Charles , Abu Raya, Maison , Vrillon, Agathe , Nudelman, Kelly N , Vemuri, Prashanthi , Day, Gregory S , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon , Wingo, Thomas S , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Maiti, Piyush , Schonhaut, Daniel R. , Hammers, Dustin B , Nudelman, Kelly , Kirby, Kala, Vemuri, Prashanthi , Beckett, Laurel , Atri, Alireza , Honig, Lawrence S. , Jones, David T., Womack, Kyle , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Annals of Neurology | March 17, 2025 | Volume: 98 | Issue: 2 | Pages: 236-248

10.1002/ana.27233 | PMID 40091774 Get It

Objective Early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) differ in many respects. Here, we address the issue of possible differences in fibrillar amyloid pathology as measured by positron emission tomography (PET), which remains unresolved due to the lack of large‐scale comparative studies. Methods Three hundred ninety‐nine cognitively impaired participants younger than 65 years of age from the multicenter Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and 450 cognitively impaired participants older than 65 years from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent clinical assessment, brain magnetic resonance imaging (MRI), and amyloid PET and were included in this study. We compared amyloid PET outcomes (positivity rate based on visual read and quantified tracer uptake expressed as Centiloids [CLs]) between the 2 cohorts and studied their association with age, sex, APOE genotype, and cognition. Results The amyloid positivity rate was higher in LEADS (78%, 95% confidence interval [CI] = 74–82) than in ADNI (71%, 95% CI = 67–75, p = 0.02). Lower Mini‐Mental State Examination (MMSE) and APOE4 genotype increased the odds of amyloid positivity in both cohorts. Visually positive scans had higher CLs in LEADS (EOAD, mean = 95.3 ± 26.1) than in ADNI (LOAD, mean = 80.9 ± 36.8, p < 0.0001), predominantly in parietal cortex/precuneus, superior temporal, and frontal cortices. In amyloid‐positive patients, (1) CLs were higher in female patients in both cohorts; (2) APOE4 carriership was associated with lower CLs in EOAD, which was not observed in LOAD; and (3) correlations between CLs and MMSE scores were significantly stronger in EOAD than in LOAD. Interpretation Differences in the burden of amyloid pathology may contribute to differences in clinical and anatomic patterns in sporadic EOAD and LOAD, and have implications for optimizing therapeutic strategies in each group. ANN NEUROL 2025;98:236–248
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Gajjar, Amar , Mahajan, Anita , Canan, Liz, Chi, Susan , Cluster, Andrew , Cole, Bonnie , Darlington, Wendy , Dorris, Kathleen , Elster, Jennifer , Franson, Andrea , Helgager, Jeffrey, Lin, Chi , Metrock, Laura, Nanda, Ronica H. , Partap, Sonia , Plant, Ashley , Reynolds, Renée M. , Stearns, Duncan , Storm, Phillip, Wang, Leo D. , Whipple, Nicholas , Zaky, Wafik , McMillian, Nicole R., Ramakrishnan, Swathi , Franson, Andrea , Bale, Tejus , Bowers, Daniel C. , Cohen, Kenneth J. , Coven, Scott L. , Ermoian, Ralph P. , George, Elizabeth , Landi, Daniel B. , Palmer, Joshua D. , Pruthi, Sumit , Wang, Anthony

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 113-130

10.6004/jnccn.2025.0012 | PMID 40073837 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents. This article summarizes the studies and panel discussion that serve as the rationale for comprehensive care recommendations included in the NCCN Guidelines for Pediatric Central Nervous System Cancers.
Exploration of Genetic Liability to Insomnia and Substance Use Disorders in Patients With Bipolar Disorder
Beaupre, Lindsay Melhuish , Batzler, Anthony , Sánchez-Ruiz, Jorge A. , Romo‐Nava, Francisco , Jenkins, G. Douglas , Waller, T. Cameron , Skime, Michelle , Frye, Mark A. , Melhuish Beaupre, Lindsay M , Sanchez-Ruiz, Jorge A , Kolla, Bhanu Prakash , Romo-Nava, F , Pazdernik, Vanessa , Jenkins, Gregory, Frye, Mark , Biernacka, Joanna , Coombes, Brandon J. , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

Bipolar Disorders | March 12, 2025 | Volume: 27 | Issue: 4 | Pages: 280-288

10.1111/bdi.70018 | PMID 40007167 Get It

ABSTRACTBackgroundInsomnia and substance use disorders (SUD) are common comorbidities of bipolar disorder (BD). Genome‐wide association studies (GWAS) have uncovered shared genetic contributions to insomnia and BD as well as SUDs and BD. Electronic health record (EHR) derived phenotypes (phecodes) and questionnaire data were used to examine the relationship between insomnia genetic liability and SUDs in BD.Methods40,839 participants from the Mayo Clinic Bipolar Disorder Biobank (BD Biobank; n = 774) and Mayo Clinic Biobank (n = 485 BD cases, n = 39,580 controls) were included in the analyses of diagnosis (phecode) outcomes (insomnia, SUD, alcohol use disorder [AUD] and tobacco use disorder [TUD]). Analyses of specific SUD outcomes obtained through the BD Biobank questionnaire included 1789 cases and considered BD subtype. Logistic regression was used to test for associations between insomnia polygenic risk scores (PRS) and insomnia and SUD outcomes in BD cases and controls.ResultsInsomnia PRS was associated with having an insomnia diagnosis (phecode) in the EHR in controls (OR = 1.19, p = 9.64e‐33) but not in BD cases (OR = 1, p = 0.95). Associations between insomnia PRS and SUD diagnoses were significant in BD cases and controls, with the association being stronger in BD cases (interaction p = 0.024). In the BD Biobank data, the insomnia PRS was associated with increased odds of AUD (OR = 1.19, p = 4.26e‐04), TUD (OR = 1.21, p = 1.25e‐05) and cannabis use disorder (OR = 1.16, p = 4.19e‐03).ConclusionThe effect of genetic predisposition to insomnia on SUD risk may be stronger in BD cases than in controls, which could have clinical care implications for individuals with BD and comorbid SUD.
Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia
Abeykoon, Jithma P. , Perera, Nirosha D. , Gustine, Joshua , Ramirez‐Gamero, Andres , Varettoni, Marzia , Tedeschi, Alessandra , Cavalloni, Chiara, Frustaci, Anna Maria , Pederson, Levi , Zanwar, Saurabh , Kapoor, Prashant , Kyle, Robert A. , Geyer, Susan M. , Ansell, Stephen M. , Paludo, Jonas , Sarosiek, Shayna , Varettoni, Marzia , Frustaci, Anna Maria , Pederson, Levi D , Zanwar, Saurabh S , Habermann, Thomas , Witzig, T.E. , Gertz, Morie A , Treon, Steven , Castillo, Jorge J , Ansell, Stephen M , Paludo, Jonas , Habermann, Thomas M. , Witzig, Thomas E. , Gertz, Morie A. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: 6 | Pages: 980-986

10.1002/ajh.27663 | PMID 40062689 Get It

ABSTRACT As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed‐duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis. A total of 440 patients with WM treated with frontline fixed‐duration regimens were included. Attaining a major response (MaR) was associated with superior outcomes, including significantly longer OS. The estimated 5‐year PFS rates for patients with MaR at 6 months versus not were 50% versus 32%, respectively, p < 0.001, and the estimated 5‐year OS rates for patients with MaR at 6 months versus not were 89% versus 70%, respectively, p < 0.001. In a multivariable analysis, MaR at 6 months was independently associated with superior PFS (HR 0.66, p = 0.007) and OS (HR 0.28, p < 0.001). Similar results were seen when considering deeper responses (CR + VGPR vs. PR). Depth of response at 6 months is an important prognostic marker in WM and an independent predictor of PFS and OS. These results support its utilization as a suitable endpoint in clinical studies in WM.
Outcomes after en bloc resection with sacrectomy of advanced colorectal carcinomas that invade the sacrum: a multiinstitutional descriptive series
Pieters, Thomas A. , Elsamadicy, Aladine A. , Pennington, Zach , Najjar, Salem , Ber, Roee , Efron, Jonathan E., Gearhart, Susan L. , Safar, Bashar , Wolinsky, Jean-Paul, Sciubba, Daniel M. , Lo, Sheng-Fu Larry , Pennington, Zach , Hersh, Andrew M. , Santangelo, Gabrielle , Hung, Bethany , Atallah, Chady , Wolinsky, Jean‐Paul

Mayo Clinic

Journal of Neurosurgery: Spine | March 7, 2025 | Volume: 42 | Issue: 5 | Pages: 598-604

10.3171/2024.10.spine24391 | PMID 40053935 Get It

OBJECTIVE Management of locally invasive colorectal carcinoma at any stage currently involves surgical excision followed by chemoradiotherapy; however, the prognosis is poor, with a 5-year overall survival (OS) of only 5%. Failure to achieve gross-total resection is associated with poorer OS, and patients with residual tumor postresection (R1 or R2 resection) have a median OS of 7 months compared with 23 months in those who undergo resection with negative margins (R0 resection). For tumors that have invaded the sacrum, sacrectomy becomes necessary to achieve R0 resection. The objective of this study was to provide a descriptive multicenter account of resection for locally invasive colorectal carcinoma with sacral invasion, focusing on the association of tumor morphometry with surgical planning and perioperative outcomes. METHODS Demographic, comorbidity, clinical, tumor-specific, operative characteristic, and outcome data were collected on all patients who underwent resection of colorectal carcinoma with concurrent sacral resection between January 2005 and May 2022. Patients were grouped into those having undergone surgery for purely palliative intent, or those with resection with attempt at local control and dichotomized into level of osteotomy (either proximal or distal to the S2–3 level). RESULTS Twenty-two patients (median age 50.5 [IQR 43.3–60.0] years, 54.5% female) underwent sacrectomy for colorectal carcinoma. Operative records indicated intent for local control in 14 patients and palliative in the remaining 8 patients. Palliative surgical intent was based primarily on the presence of distant metastases. There was no significant difference in median local progression-free survival between patients undergoing osteotomy proximal to the S2–3 level and those undergoing osteotomy distal to the S2–3 level. CONCLUSIONS En bloc resection is believed to offer the best local control in patients with locally invasive colorectal carcinoma. The present descriptive series highlights outcomes of en bloc resection with partial or full sacrectomy in patients with tumors showing local extension into the sacrum. Complications are common, most often in the form of wound dehiscence or infection, and many patients require placement in a rehabilitation or intermediate-care facility upon discharge. However, for those with stage III (locally aggressive) disease, median OS exceeds 16 years, suggesting that such aggressive management with en bloc resection may be warranted in properly selected patients.
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin
Kleinstern, Geffen , Robinson, Dennis P. , Rimsza, Lisa M. , Larson, Melissa C. , King, Rebecca L. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Ansell, Stephen M. , Maurer, Matthew J. , Feldman, Andrew L. , Novak, Anne J. , Slager, Susan L , Novak, Anne J , Habermann, Thomas , Cerhan, James R , Feldman, Andrew L , Maurer, Matthew , Rimsza, Lisa M , Larson, Melissa C , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 6, 2025 | Volume: 34 | Issue: 5 | Pages: 780-787

10.1158/1055-9965.epi-24-1610 | PMID 40047811 Get It

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is clinically heterogeneous, and gene expression profiling has identified at least two biologically distinct DLBCL subtypes defined by their cell of origin (COO): germinal center B cell (GCB) and activate B cell (ABC) or non-GCB. We evaluated a variety of putative DLBCL risk factors for etiologic heterogeneity by the COO in a clinic-based study of newly diagnosed DLBCL cases (N = 638) and frequency-matched controls (N = 2,253). Methods: The COO was determined on formalin-fixed, paraffin-embedded tumor tissue, with DLBCL classified as GCB (N = 283), non-GCB (N = 188), or undetermined/missing (N = 167; mainly because of lack of tissue). Multivariable logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: We identified heterogeneity by the COO for low socioeconomic status (SES), which was only associated with non-GCB DLBCL (OR = 1.88 for low vs. average SES; 95% CI, 1.08–3.27); alcohol use, which was only associated with GCB DLBCL (OR = 0.48 for former drinkers; 95% CI, 0.29–0.80 and OR = 0.47 for current drinkers; 95% CI, 0.32–0.71); and borderline heterogeneity for the regular use of regular/extra-strength aspirin, which was only associated with non-GCB DLBCL (OR = 0.36; 95% CI, 0.16–0.85). In contrast, there was no significant heterogeneity by the COO for family history, medical history, or other lifestyle factors. Conclusions: Although requiring confirmation, most risk factors for DLBCL did not show etiologic heterogeneity by the COO, with some notable exceptions including alcohol use, SES, and perhaps regular use of regular/extra-strength aspirin showing associations. Impact: Mechanistically, these findings suggest that most of the DLBCL risk factors evaluated here influence lymphomagenesis prior to differentiation into COO subtypes, with selected factors acting later.
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Zarif, Talal El , Denu, Ryan , Abdel‐Wahab, Noha , Freeman, Dory , Hayeck, Salim, Anderson, Élizabeth , Goodman, Rachel , Johnson, Douglas B. , Grynberg, Shirly , Shapira, Ronnie, Kwan, Jennifer M. , Long, Georgina V. , Haykal, Tarek , Kojima, Yuki , Yonemor, Kan, Trevino, Alexandra , Hui, Gavin , Drakaki, Alexandra, El‐Am, Edward , Al‐Hader, Ahmad, Babu, P. Narendra , Li, Mingjia , Jones, N. , Herrera, M., Foderaro, Simone , Kim, Chul , Sackstein, Paul , Desai, Aakash , Smith, Caleb J. , Korolewicz, James , Lopetegui‐Lia, Nerea , Funchain, Pauline , Choudhary, Arrush, Asnani, Aarti , Stukalin, Igor , Gallegos, Jesús Antonio Ocejo , Nusrat, Sanober , Malvar, Carmel, McKay, Rana R. , Neilan, Tomas G. , Naqash, Abdul Rafeh , Baena, Javier , El Zarif, Talal , Goodman, Rachel S , Kim, Chul , Desai, Aakash P , Cortellini, Alessio , Pinato, David J , Navani, Vishal , Ocejo Gallegos, Jesus Antonio , Funchain, Pauline , Long, Georgina V , Naqash, Abdul Rafeh , Grynberg, Shirly , Espinar, Javier Baena , Alaiwi, Sarah Abou , Macaron, Walid , Vasbinder, Alexi L. , Woodford, Rachel , Dent, Susan , Kojima, Yuki, Tandon, Ankita, Akhter, Nausheen , Yang, Eric H. , Kozaily, Elie , Farhat, Elias Bou , Mittra, Arjun , Jones, Nicholas, Baena, Javier, Nana, Frank Aboubakar , Parikh, Kaushal , Cortellini, Alessio , Pinato, David J. , Meyers, Daniel E. , Trent, Jonathan C. , Choueiri, Toni K. , Korolewicz, James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 3, 2025 | Volume: 13 | Issue: 3 | Pages: e009364

10.1136/jitc-2024-009364 | PMID 40032601 Get It

Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included. Treatment-related adverse events (trAEs) were graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) were evaluated by Response Evaluation Criteria in Solid Tumors V.1.1 when available. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Results Among 110 pts, median age at ICI initiation was 65 (IQR: 59–75). Median follow-up time since ICI initiation was 36 (95% CI: 26 to 51) months. Melanoma (38%, n=42) and non-small cell lung cancer (24%, n=26) were the most common. 68 (62%) patients received ICIs as first-line, and 29 (26%) patients were treated with combination anti-programmed death-1 and anti-cytotoxic T-lymphocyte antigen 4. The most common location of cardiac metastasis was in the atria (37%, n=41) and ventricles (35%, n=39). 15 patients (13.6%) had bilateral cardiac/pericardial metastasis, 44 (40%) had left-sided, and 43 (39.8%) had right-sided. At ICI initiation, 21% (n=23) had a cardiac thrombus. Cardiology referrals and cardiac MRIs at the time of cancer diagnosis were completed on 58 (53%) and 52 (47%) patients, respectively. Cardiac events occurred in 40 (36%) patients, including arrhythmias (n=14, 13%), arterial/venous emboli (n=4, 3.6%), and cardiac tamponade (n=3, 2.7%). 53 (47%) patients developed trAEs; most common were colitis/diarrhea (n=16, 15%), dermatitis (n=13, 12%), and hepatitis (n=9, 8.2%). ICI-related major cardiac trAEs occurred in 2 (1.8%) patients. 22 patients (20%) developed grade ≥3 trAE. Patients with multiple cardiac metastases had significantly lower responses to ICI-based regimens compared with patients with single cardiac metastasis (11% vs 63%, p=0.02). For melanoma, ORR, median PFS, and median OS were 38%, 9.0 months, and 28.9 months, respectively. 83% of patients with melanoma had concordant responses in overall disease burden and cardiac disease. 91 patients discontinued ICIs, and the main reason was progression or death in 55 (49%) patients. Conclusions Among patients with pre-existing cardiac metastasis, ICIs demonstrated meaningful clinical efficacy with no increase in safety signals. Most patients had concordant responses in the overall disease burden and cardiac mass. Multidisciplinary teams are crucial for the appropriate management of patients with cardiac metastasis.
Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Collin, Lindsay J. , Cushing‐Haugen, Kara L. , Terry, Kathryn L. , Goode, Ellen L. , Wu, Anna H. , Harris, Holly R. , Sasamoto, Naoko , Cramer, Daniel W. , Modugno, Francesmary , Elishaev, Esther , Moysich, Kirsten B. , Fasching, Peter A. , Pearce, Celeste Leigh , Menon, Usha , Gayther, Simon A. , Wentzensen, Nicolas , Goodman, Marc T. , George, Joshy , Talhouk, Aline , Anglesio, Michael S. , Ramus, Susan J. , Bowtell, David D.L. , Tworoger, Shelley S. , Schildkraut, Joellen M. , George, Joshy , Fu, Zhuxuan , Moysich, Kirsten , Fasching, Peter A , Pearce, Celeste Leigh , Menon, Usha , Gentry‐Maharaj, Aleksandra , Gayther, Simon A , Wentzensen, Nicolas , Goodman, Marc T , George, Joshy , Talhouk, Aline , Anglesio, Michael S , Ramus, Susan J , Bowtell, David D , Tworoger, Shelley S , Schildkraut, Joellen M , Webb, Penelope M , Doherty, Jennifer A , Cramer, Daniel W , Modugno, Francesmary , Harris, Holly R , Elishaev, Esther , Cushing-Haugen, Kara L , Fu, Zhuxuan , Webb, Penelope M. , Doherty, Jennifer A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 26, 2025 | Volume: 34 | Issue: 5 | Pages: 762-773

10.1158/1055-9965.epi-24-1143 | PMID 40009771 Get It

Abstract Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. We investigated associations between different epidemiologic risk factors and HGSC molecular subtypes. Methods: We pooled data from 11 case–control studies with epidemiologic and tumor gene expression data from custom NanoString CodeSets developed through a collaboration within the Ovarian Tumor Tissue Analysis consortium. The PrOTYPE-validated NanoString-based 55-gene classifier was used to assign HGSC gene expression subtypes. We examined associations between epidemiologic factors and HGSC subtypes in 2,070 cases and 16,633 controls using multivariable-adjusted polytomous regression models. Results: Among the 2,070 HGSC cases, 556 (27%) were classified as C1.MES, 340 (16%) as C5.PRO, 538 (26%) as C2.IMM, and 636 (31%) as C4.DIF. The key factors, including oral contraceptive use, parity, breastfeeding, and family history of ovarian cancer, were similarly associated with all subtypes. Heterogeneity was observed for several factors. Former smoking [OR = 1.25; 95% confidence interval (CI) = 1.03, 1.51] and genital powder use (OR = 1.42; 95% CI = 1.08, 1.86) were uniquely associated with C2.IMM. History of endometriosis was associated with C5.PRO (OR = 1.46; 95% CI = 0.98, 2.16) and C4.DIF (OR = 1.27; 95% CI = 0.94, 1.71) only. Family history of breast cancer (OR = 1.44; 95% CI = 1.16, 1.78) and current smoking (OR = 1.40; 95% CI = 1.11, 1.76) were associated with C4.DIF only. Conclusions: This study observed heterogeneous associations of epidemiologic and modifiable factors with HGSC molecular subtypes. Impact: The different patterns of associations may provide key information about the etiology of the four subtypes.
Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).
Roy, Soumyajit , Eastham, James A., Beltran, Himisha , Kishan, Amar U. , Jia, Angela Y. , García, Jorge A. , McKay, Rana R. , Sartor, Alton Oliver, Halabi, Susan , Feng, Felix Y. , Halabi, Susan , Sun, Yilun , Gleave, Martin , Zaorsky, Nicholas G. , Small, Eric J. , Nguyen, Paul L. , Attard, Gerhardt , Rosenthal, Seth A. , Morris, Michael J. , Sandler, Howard M. , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 309-309

10.1200/jco.2025.43.5_suppl.309 Get It

309 Background: Standard of care (SOC) treatment options for HR-PCa include RT with long-term androgen deprivation (LT-ADT) or RP with selective use of post-operative RT +/- androgen deprivation therapy (ADT). The optimal treatment approach has been assessed in retrospective population-based and multi-center comparisons, which have yielded mixed results with substantial bias. Therefore, we conducted an emulated randomized comparison of RT vs RP in HR-PCa leveraging patients enrolled in RCTs. Methods: We searched Medline for RCTs in HR-PCa with a SOC arm of an RT- or RP-based regimen. Inclusion required similar experimental treatment and contemporaneous enrollment in the same country to reduce bias. This identified 2 trials, NRG/RTOG 0521 (RT+LT-ADT +/- 6 cycles docetaxel [doce]), and CALGB 90203 (RP +/- neoadjuvant 6 cycles doce and ADT). Due to inherent difference in the biochemical recurrence criteria after RT vs RP, we chose inverse probability of treatment weighted (IPTW) cumulative incidence of distant metastasis (DM) as the primary endpoint, considering deaths as competing events. Death after DM was measured to create a harmonized metric of deaths likely attributed to PCa. To assess potential residual selection bias, death without DM to capture non-cancer associated deaths was analyzed. Results: Overall, 1290 patients (RT n=557, RP n=733) were included, with similar median follow-up of 6.4 years. Prior to IPTW, RP patients were significantly younger with lower baseline PSA compared to RT patients. Adjuvant (18%) and salvage therapy (44%) was used in RP cohort. Cumulative incidence of DM was significantly lower in patients who underwent RT compared to RP (8-year DM: 16% vs 23%; p=0.01; subdistribution hazard ratio [sHR] 0.48 [95%CI 0.34-0.69], p<0.001). 8-year rates of death after DM were 10% vs 8% (p=0.72) in the RP and RT patients, respectively. RT patients had significantly greater risk of death without DM (HR 2.09 [1.01-4.34], p=0.048) with early differences measured. On a cross-arm comparison, 8-year cumulative incidence of DM when comparing SOC RT+LT-ADT group versus the doce+ADT+RP group was 18% vs 21%, respectively (sHR 0.75 [0.45-1.24], p=0.26). Conclusions: HR-PCa patients enrolled on RCTs had significantly lower incidence of DM with an RT-based strategy compared to an RP-based approach. Longer follow-up is needed to assess deaths attributed to PCa. Despite the strengths of the comparison (use of cooperative group RCT data, contemporaneous enrollment in the same country, patients fit enough for chemotherapy, and IPTW adjustments) there appears to be residual unmeasured bias, as expected, based on greater early deaths without DM in the RT arm. Utilization of post-operative radiotherapy and ADT+Doce may mitigate differences between RP and SOC RT+LT-ADT.